Comparison 9. Methotrexate versus placebo ≤ 6 months (sensitivity analysis).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Disease response (PsARC) ‐ sensitivity analysis	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
2 Function (HAQ) ‐ sensitivity analysis	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
3 Disease activity (DAS28‐ESR) ‐ sensitivity analysis	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
4 Disease response (ACR20) ‐ sensitivity analysis	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
5 Pain ‐ sensitivity analysis	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
6 Skin disease ‐ sensitivity analysis	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
7 Patient global assessment of disease activity ‐ sensitivity analysis	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
8 Physician global assessment of disease activity ‐ sensitivity analysis	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
9 Swollen joint count ‐ sensitivity analysis	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
10 Tender joint count ‐ sensitivity analysis	1		Mean Difference (IV, Random, 95% CI)	Totals not selected